Agios Pharmaceuticals, Inc.
NASDAQ:AGIOBiotechnology
+$0.50 today
- Market cap
- $1.78B
- Beta
- 0.59
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$7.19
Volume 0.60M
Average 1.11M
AGIO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Agios Pharmaceuticals, Inc.NASDAQ: AGIO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $1.36M rose 6.7% year over year, ahead of the -5.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 7.7% from the prior quarter. Over 3 fiscal years it compounded at -15.4% a year.
Context
- Depreciation & amortization amounted to 9.6% of revenue in FY2025, down 5.9 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +6.7% holds above the trailing-twelve-month pace of -5.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 5.18M USD
- Year-over-year change
- -8.4%
- 4-year CAGR
- -13.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.18M | -8.4% |
| FY2024 | 2024-12-31 | 5.65M | -14.6% |
| FY2023 | 2023-12-31 | 6.62M | -22.7% |
| FY2022 | 2022-12-31 | 8.56M | -7.3% |
| FY2021 | 2021-12-31 | 9.24M | — |
Depreciation & Amortization vs competitors
How AGIO compares with its peers on the latest reported figures
- AGIO's LTM Mar 2026 depreciation & amortization of $5.26M is the 6th largest of the 7 companies compared; the peer median is $11.08M.
- Its year-over-year change of -5.7% is the 5th highest of 7, against a peer median of +42.6%.
- Depreciation & amortization amounts to 8.0% of revenue for AGIO, versus a peer median of 2.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $55.3M | +97.1% | -33.0% | 5.5% | |
| LTM Jun 2026 | $25.95M | +7.1% | +95.6% | 4.2% | |
| LTM Mar 2026 | $13.62M | -61.8% | +24.3% | 2.0% | |
| LTM Mar 2026 | $8.54M | -34.4% | — | 2.3% | |
| LTM Jun 2026 | $5.95M | +365.1% | -1.1% | 0.6% | |
| LTM Mar 2026 | $5.26M | -5.7% | -15.4% | 8.0% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $358K | +78.1% | +46.7% | — |
| Peer median (excluding AGIO) | $11.08M | +42.6% | +24.3% | 2.3% | |
Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (356.51M) | (231.8M) | (352.09M) | 673.73M | (412.78M) |
| Depreciation & Amortization | 9.24M | 8.56M | 6.62M | 5.65M | 5.18M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 53.51M | 49.3M | 44.77M | 42.85M | 52.55M |
| Change in Working Capital | (36.82M) | (16.43M) | (19.06M) | (19.77M) | (33.04M) |
| Accounts Receivables | (4.38M) | (2.21M) | (604K) | (1.3M) | (6.47M) |
| Inventory | 0 | (8.49M) | (10.58M) | (8.54M) | (5.3M) |
| Accounts Payables | 1.86M | 3.44M | (8.73M) | 6.6M | 1.75M |
| Other Working Capital | (34.31M) | (9.17M) | 864K | (16.53M) | (23.02M) |
| Other Non-Cash Items | (76.74M) | (119.1M) | 23.69M | (1.09B) | 15.12M |
| Operating Cash Flow | (407.32M) | (309.48M) | (296.06M) | (389.84M) | (372.98M) |
| Capital Expenditures | (5.74M) | (4.88M) | (999K) | (1.69M) | (4.32M) |
| Acquisitions (Net) | 0 | 132.75M | 0 | 40K | 0 |
| Purchases of Investments | (1.38B) | (1.03B) | (417.93M) | (1.54B) | (641.76M) |
| Sales of Investments | 829.8M | 1.15B | 674.68M | 818.38M | 1.03B |
| Other Investing Activities | 1.8B | 0 | (16.18M) | 1.09B | (10M) |
| Investing Cash Flow | 1.25B | 243.26M | 239.58M | 363.44M | 377.18M |
| Debt Repayment | (578K) | (331K) | 0 | 0 | 0 |
| Common Stock Issued | 0 | 2.68M | 5.43M | 14.44M | 8.68M |
| Common Stock Repurchased | (802.49M) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 37.3M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | (765.77M) | 2.35M | 5.43M | 14.44M | 8.68M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 75.69M | (63.87M) | (51.05M) | (11.96M) | 12.88M |
| Free Cash Flow | (413.06M) | (314.36M) | (297.06M) | (391.53M) | (377.29M) |
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.